Dr. Julie Margenthaler, M.D.
Claim this profileWashington University School of Medicine
Studies Breast Cancer
Studies Dense Breasts
10 reported clinical trials
16 drugs studied
Area of expertise
1Breast Cancer
ER positive
HER2 negative
Stage I
2Dense Breasts
Affiliated Hospitals
Clinical Trials Julie Margenthaler, M.D. is currently running
Ultra-Hypofractionated vs. Hypofractionated Radiation
for Breast Cancer
In breast cancer patients with nodal involvement, numerous studies have demonstrated that adjuvant radiation therapy reduces the risk of local recurrence, regional recurrence, and distant metastases, in addition to improving survival. The dose and fractionation for adjuvant breast radiation therapy has evolved over time, as novel schedules have been compared to the current standard of care. Hypofractionated radiation therapy (266 cGy per fraction x 15-16 fractions over 3 weeks) has been shown to result in equivalent oncologic outcomes, as well as equivalent acute and late toxicity, when compared to standard fractionation (200 cGy per fraction x 25 fractions over 5 weeks). Subsequently, hypofractionated breast radiation has become the current standard of care. More recently, ultra-hypofractionated breast radiation (520 cGy per fraction x 5 fractions over 1 week) was shown in a randomized trial to be non-inferior to hypofractionated radiation when treating the breast after lumpectomy. However, the efficacy and toxicity of using ultra-hypofractionated radiation therapy when also treating the regional nodes has not been reported. This is important, as there is greater radiation exposure to several normal tissues, such as the arm/shoulder, brachial plexus, normal lymphatics, heart, and lung, when treating the regional nodes. In this randomized study, the investigators aim to compare the tolerability and efficacy of ultra-hypofractionated breast/chest wall and regional nodal radiation (SWIFT RT) against hypofractionated radiation (RT). The investigators will evaluate acute and late toxicity, oncologic outcomes (including local recurrence, regional recurrence, distant metastasis, and overall survival), cosmesis, and patient-reported quality of life. The investigators will collect blood samples for correlative studies of biomarkers of fibrosis and cardiac toxicity.
Recruiting1 award Phase 29 criteria
Fluorescence Imaging
for Breast Cancer Surgery
The investigators' preclinical data have demonstrated the feasibility of fluorescence-guided tumor resection by Cancer Vision Goggles (CVG) with LS301 in animal models. In this study, the investigators will conduct intraoperative imaging procedures that have minimal interference with ongoing surgery. The underlying hypothesis is that the accurate detection of all cancer cells highlighted by LS301 during surgery will reduce the number of breast cancer patients with margin positivity to less than 5%, compared to the current surgical paradigm of greater than 20%. The pilot study will obtain critical data required to address the larger question of surgical margin assessment in a full Phase I clinical trial. Phase 1: to determine the safety and optimal imaging dose of LS301 injected in breast cancer patients. Phase 2: to determine the ability of this novel fluorescence imaging agent to predict the presence of positive margins around partial mastectomy specimens and positive SLNs during surgical therapy for breast cancer.
Recruiting1 award Phase 1 & 24 criteria
More about Julie Margenthaler, M.D.
Clinical Trial Related8 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Julie Margenthaler, M.D. has experience with
- LS301
- Denosumab
- Mammaglobin-A DNA Vaccine
- Anastrozole
- Fulvestrant
- Exemestane
Breakdown of trials Julie Margenthaler, M.D. has run
Breast Cancer
Dense Breasts
Uterine Tumors
Post-Mastectomy Breast Reconstruction
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Julie Margenthaler, M.D. specialize in?
Julie Margenthaler, M.D. focuses on Breast Cancer and Dense Breasts. In particular, much of their work with Breast Cancer has involved ER positive patients, or patients who are HER2 negative.
Is Julie Margenthaler, M.D. currently recruiting for clinical trials?
Yes, Julie Margenthaler, M.D. is currently recruiting for 4 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Julie Margenthaler, M.D. has studied deeply?
Yes, Julie Margenthaler, M.D. has studied treatments such as LS301, Denosumab, Mammaglobin-A DNA Vaccine.
What is the best way to schedule an appointment with Julie Margenthaler, M.D.?
Apply for one of the trials that Julie Margenthaler, M.D. is conducting.
What is the office address of Julie Margenthaler, M.D.?
The office of Julie Margenthaler, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.